HomeCompareIKTSY vs PFE

IKTSY vs PFE: Dividend Comparison 2026

IKTSY yields 4.13% · PFE yields 6.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 IKTSY wins by $304.1K in total portfolio value
10 years
IKTSY
IKTSY
● Live price
4.13%
Share price
$48.88
Annual div
$2.02
5Y div CAGR
48%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$353.7K
Annual income
$181,955.60
Full IKTSY calculator →
PFE
Pfizer Inc.
● Live price
6.13%
Share price
$28.08
Annual div
$1.72
5Y div CAGR
13.2%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$49.6K
Annual income
$26,258.71
Full PFE calculator →

Portfolio growth — IKTSY vs PFE

📍 IKTSY pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodIKTSYPFE
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, IKTSY + PFE cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
IKTSY pays
PFE pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

IKTSY
Annual income on $10K today (after 15% tax)
$351.35/yr
After 10yr DRIP, annual income (after tax)
$154,662.26/yr
PFE
Annual income on $10K today (after 15% tax)
$520.66/yr
After 10yr DRIP, annual income (after tax)
$22,319.90/yr
At 15% tax rate, IKTSY beats the other by $132,342.36/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of IKTSY + PFE for your $10,000?

IKTSY: 50%PFE: 50%
100% PFE50/50100% IKTSY
Portfolio after 10yr
$201.6K
Annual income
$104,107.16/yr
Blended yield
51.63%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PFE right now

IKTSY
Analyst Ratings
2
Buy
1
Hold
Consensus: Buy
Altman Z
4.5
Piotroski
6/9
PFE
Analyst Ratings
16
Buy
22
Hold
1
Sell
Consensus: Hold
Price Target
$27.50
-2.1% upside vs current
Range: $24.00 — $35.00
Altman Z
2.0
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

IKTSY buys
0
PFE buys
0
No recent congressional trades found for IKTSY or PFE in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricIKTSYPFE
Forward yield4.13%6.13%
Annual dividend / share$2.02$1.72
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR48%13.2%
Portfolio after 10y$353.7K$49.6K
Annual income after 10y$181,955.60$26,258.71
Total dividends collected$314.0K$58.3K
Payment frequencyquarterlyquarterly
SectorStockHealthcare
Analyst consensusBuyHold

Year-by-year: IKTSY vs PFE ($10,000, DRIP)

YearIKTSY PortfolioIKTSY Income/yrPFE PortfolioPFE Income/yrGap
1← crossover$11,312$611.76$9,153$693.39+$2.2KIKTSY
2$13,061$957.17$8,593$849.25+$4.5KIKTSY
3$15,504$1,528.65$8,336$1,066.78+$7.2KIKTSY
4$19,099$2,509.87$8,437$1,384.80+$10.7KIKTSY
5$24,712$4,276.62$9,013$1,875.40+$15.7KIKTSY
6$34,096$7,653.96$10,306$2,680.72+$23.8KIKTSY
7$51,090$14,606.82$12,820$4,101.38+$38.3KIKTSY
8$84,939$30,273.44$17,673$6,826.70+$67.3KIKTSY
9$160,502$69,617.06$27,543$12,591.86+$133.0KIKTSY
10$353,693$181,955.60$49,560$26,258.71+$304.1KIKTSY

IKTSY vs PFE: Complete Analysis 2026

IKTSYStock

Intertek Group plc provides quality assurance solutions to various industries in the United Kingdom, the United States, and internationally. It operates in three segments: Products, Trade, and Resources. The Products segment offers assurance, testing, inspection, and certification services (ATIC), including laboratory safety, quality and performance testing, second-party supplier auditing, sustainability analysis, products assurance, vendor compliance, process performance analysis, facility plant and equipment verification, and third party certification. This segment serves a range of industries, including textiles, footwear, toys, hardlines, home appliances, consumer electronics, information and communication technology, automotive, aerospace, lighting, building products, industrial and renewable energy products, food and hospitality, healthcare and beauty, and pharmaceuticals. The Trade segment provides cargo inspection, analytical assessment, calibration, and related research and technical services to the petroleum and biofuels industries; inspection services to governments and regulatory bodies to support trade activities; and analytical and testing services to agricultural trading companies and growers. The Resources segment offers technical inspection, asset integrity management, analytical testing, and ongoing training services for the oil, gas, nuclear, and power industries. This segment also provides a range of ATIC service solutions to the mining and minerals exploration industries covering the resource supply chain from exploration and resource development, through to production, shipping, and commercial settlement. The company also offers cyber security services. Intertek Group plc was founded in 1885 and is based in London, the United Kingdom.

Full IKTSY Calculator →

PFEHealthcare

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Full PFE Calculator →
📬

Get this IKTSY vs PFE comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

IKTSY vs SCHDIKTSY vs JEPIIKTSY vs OIKTSY vs KOIKTSY vs MAINIKTSY vs JNJIKTSY vs MRKIKTSY vs ABBV

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.